319 related articles for article (PubMed ID: 32209821)
1. Recent progress in treating advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2020 May; 32(3):210-215. PubMed ID: 32209821
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Gourdin T
Curr Opin Oncol; 2018 May; 30(3):159-164. PubMed ID: 29553949
[TBL] [Abstract][Full Text] [Related]
3. Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal.
Gourdin T
Curr Opin Oncol; 2021 May; 33(3):252-256. PubMed ID: 33818543
[TBL] [Abstract][Full Text] [Related]
4. Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Gourdin T
Curr Opin Oncol; 2019 May; 31(3):188-193. PubMed ID: 30925537
[TBL] [Abstract][Full Text] [Related]
5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
6. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
7. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
8. Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents.
Starosta SB; Savage SJ
Curr Urol Rep; 2018 Jul; 19(9):73. PubMed ID: 30030649
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions.
Gourdin T
Curr Opin Oncol; 2022 May; 34(3):228-233. PubMed ID: 35671121
[TBL] [Abstract][Full Text] [Related]
11. Emerging Therapies in Metastatic Prostate Cancer.
Sonnenburg DW; Morgans AK
Curr Oncol Rep; 2018 Apr; 20(6):46. PubMed ID: 29644451
[TBL] [Abstract][Full Text] [Related]
12. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Liu JJ; Zhang J
Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
[TBL] [Abstract][Full Text] [Related]
13. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
Pant MK; Abughaban A; Aragon-Ching JB
Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
[TBL] [Abstract][Full Text] [Related]
14. Treatments and challenges in advanced prostate cancer.
Gourdin T; Velayati A
Curr Opin Oncol; 2023 May; 35(3):200-205. PubMed ID: 36966494
[TBL] [Abstract][Full Text] [Related]
15. Progress in the treatment of advanced prostate cancer.
Sternberg CN; Petrylak DP; Madan RA; Parker C
Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
[TBL] [Abstract][Full Text] [Related]
16. Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Vaishampayan UN
Curr Opin Oncol; 2015 May; 27(3):201-8. PubMed ID: 25811344
[TBL] [Abstract][Full Text] [Related]
17. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract][Full Text] [Related]
18. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
20. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]